Terms: = Ovarian cancer AND AKAP9, AKAP350, 10142, ENSG00000127914, KIAA0803, Q99996, AKAP450, YOTIAO, PRKA9, HYPERION, MU-RMS-40_16A, CG-NAP AND Prognosis
1 results:
1. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.
Di Liello R; Arenare L; Raspagliesi F; Scambia G; Pisano C; Colombo N; Frezzini S; Tognon G; Artioli G; Gadducci A; Lauria R; Ferrero A; Cinieri S; De Censi A; Breda E; Scollo P; De Giorgi U; Lissoni AA; Katsaros D; Lorusso D; Salutari V; Cecere SC; Lapresa M; Nardin M; Bogani G; Distefano M; Greggi S; Gargiulo P; Schettino C; Gallo C; Daniele G; Califano D; Perrone F; Pignata S; Piccirillo MC
Int J Gynecol Cancer; 2021 Oct; 31(10):1348-1355. PubMed ID: 34462317
[TBL] [Abstract] [Full Text] [Related]
